Crinetics Pharmaceuticals & Vertex Pharmaceuticals

Crinetics Pharmaceuticals: Crinetics is being acquired by Vertex for $85 per share, providing shareholders with a premium. Its key assets include approved drug Palsonify and late-stage candidate atumelnant.

Vertex Pharmaceuticals: Vertex is the acquirer, paying $10 billion cash to gain Crinetics' endocrine portfolio. The deal supports Vertex's diversification strategy and is expected to add $5 billion in peak revenue, but carries execution risk.

Crinetics Pharmaceuticals: Crinetics is being acquired by Vertex for $10 billion, adding endocrine disorder treatments to Vertex's portfolio. The deal is expected to close in Q3 and is likely to provide a significant premium to Crinetics shareholders.

Vertex Pharmaceuticals: Vertex raised its annual revenue forecast and reported strong Q2 results, driven by cystic fibrosis drug sales. The company is also acquiring Crinetics to expand beyond cystic fibrosis, which could enhance long-term growth prospects.

Crinetics Pharmaceuticals: Target of investigation regarding its sale to Vertex Pharmaceuticals; shareholders may receive $85 per share, but the inquiry could affect the deal.

Vertex Pharmaceuticals: Acquirer in the Crinetics deal; the investigation may scrutinize the transaction terms.

Crinetics Pharmaceuticals: Crinetics Pharmaceuticals was acquired by Vertex, contributing to the favorable M&A environment.

Vertex Pharmaceuticals: Vertex's acquisition of Crinetics Pharmaceuticals is part of the M&A wave boosting biotech sentiment.